Verona Pharma has a pleasing habit of delivering important trial results on schedule, and this morning’s announcement, confirming the completion of recruitment in the Phase IIb trial of nebulised ensifentrine in moderateto-severe COPD, is no exception. We continue to look forward to data from the 416-patient, 46-centre trial around year-end, to be followed by an end-of-Phase II meeting with the FDA in H1 2020e and the start of Phase III trials in 2020, in line with previous guidance. Po
17 Oct 2019
Ensifentrine trial on track and fully recruited: data around end-2019e
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Ensifentrine trial on track and fully recruited: data around end-2019e
Verona Pharma plc Sponsored ADR (VRNA:NAS) | 0 0 0.0%
- Published:
17 Oct 2019 -
Author:
Jens Lindqvist -
Pages:
3
Verona Pharma has a pleasing habit of delivering important trial results on schedule, and this morning’s announcement, confirming the completion of recruitment in the Phase IIb trial of nebulised ensifentrine in moderateto-severe COPD, is no exception. We continue to look forward to data from the 416-patient, 46-centre trial around year-end, to be followed by an end-of-Phase II meeting with the FDA in H1 2020e and the start of Phase III trials in 2020, in line with previous guidance. Po